Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,741 to 3,760 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| EZ/Simva 10/40 mg vs Placebo: Percutaneous Coronary Intervention (PCI) | 8 of 944 17 of 929 | -1.0 points -2.1 to 0.1 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Coronary Artery Bypass Grafting (CABG) | 69 of 944 100 of 929 | -3.5 points -6.1 to -0.9 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events) | 148 of 944 187 of 929 | -4.5 points -7.9 to -1.0 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Death Due to Cancer | 39 of 944 23 of 929 | 1.7 points 0.0 to 3.3 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Aortic Valve Replacement (AVR) | 267 of 944 278 of 929 | -1.6 points -5.7 to 2.5 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Nonfatal Myocardial Infarction (MI) | 17 of 944 26 of 929 | -1.0 points -2.4 to 0.4 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Cardiovascular Death | 47 of 944 56 of 929 | -1.0 points -3.2 to 1.0 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events) | 308 of 944 326 of 929 | -2.5 points -6.7 to 1.8 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS) | 25 of 944 23 of 929 | 0.2 points -1.3 to 1.7 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Nonhemorrhagic Stroke | 33 of 944 29 of 929 | 0.4 points -1.3 to 2.0 | 1,873 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| EZ/Simva 10/40 mg vs Placebo: Incident Cancer | 105 of 943 70 of 929 | 3.6 points 1.0 to 6.3 | 1,872 | NCT00092677 An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED) |
| Mirabegron 50 mg vs Solifenacin 5 mg: serious adverse events | 14 of 936 13 of 934 | 0.1 points -1.0 to 1.3 | 1,870 | NCT01638000 A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. |
| Prospective Group vs Retrospective Arm: Wound Infection After Open Heart Surgery | 4 of 272 17 of 1,597 | 0.4 points -0.7 to 2.7 | 1,869 | NCT02020018 Negative Pressure Wound Therapy for Prevention of Poststernotomy Infection |
| EVO100 Gel vs Placebo Gel: serious adverse events | 4 of 926 9 of 937 | -0.5 points -1.4 to 0.3 | 1,863 | NCT04553068 Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection |
| Ticagrelor In-Hosp vs Ticagrelor Pre-Hosp: serious adverse events | 143 of 950 140 of 908 | -0.4 points -3.6 to 2.9 | 1,858 | NCT01347580 A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI) |
| Spiriva Respimat + Striverdi Respimat vs Spiriva 18 mcg + Striverdi Respimat: serious adverse events | 30 of 1,298 12 of 560 | 0.2 points -1.5 to 1.5 | 1,858 | NCT02173769 Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy |
| Cocoa Extract vs Cocoa Extract Placebo: Incident Mild Cognitive Impairment | 47 of 916 63 of 940 | -1.6 points -3.7 to 0.6 | 1,856 | NCT03035201 COcoa Supplement and Multivitamin Outcomes Study for the Mind |
| Multivitamin vs Multivitamin Placebo: Incidence of Mild Cognitive Impairment Among Those Free at Baseline | 53 of 920 57 of 936 | -0.3 points -2.5 to 1.8 | 1,856 | NCT03035201 COcoa Supplement and Multivitamin Outcomes Study for the Mind |
| Genotype-Guided Therapy vs Conventional Therapy: Occurrence of the a Major Adverse Cardiovascular Event in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | 35 of 903 54 of 946 | -1.8 points -3.8 to 0.1 | 1,849 | NCT01742117 Tailored Antiplatelet Therapy Following PCI |
| Genotype-Guided Therapy vs Conventional Therapy: Thrombolysis in Myocardial Infarction Major or Minor Bleeding in Subjects Identified as CPY2C19 LOF Carriers by TaqMan. | 16 of 903 14 of 946 | 0.3 points -0.9 to 1.5 | 1,849 | NCT01742117 Tailored Antiplatelet Therapy Following PCI |
Code
curl "https://conductscience.org/api/comparisons/v1?page=188"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=188
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00092677-6e8c9d3b",
"title": "EZ/Simva 10/40 mg vs Placebo: Percutaneous Coronary Intervention (PCI)",
"summary": "8 of 944 against 17 of 929; risk difference -1.0 points, 95% interval -2.1 to 0.1; NCT00092677, An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)",
"record": "/library/comparisons/NCT00092677-6e8c9d3b",
"nct_id": "NCT00092677",
"kind": "outcome",
"participants": 1873,
"risk_difference": {
"value": -0.0098246702304282,
"lower": -0.021413042130547434,
"upper": 0.0008237209434589169
},
"group_1": "8 of 944",
"group_2": "17 of 929",
"difference": "-1.0 points",
"interval": "-2.1 to 0.1",
"trial_title": "An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)"
},
{
"id": "NCT00092677-95642c0a",
"title": "EZ/Simva 10/40 mg vs Placebo: Coronary Artery Bypass Grafting (CABG)",
"summary": "69 of 944 against 100 of 929; risk difference -3.5 points, 95% interval -6.1 to -0.9; NCT00092677, An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)",
"record": "/library/comparisons/NCT00092677-95642c0a",
"nct_id": "NCT00092677",
"kind": "outcome",
"participants": 1873,
"risk_difference": {
"value": -0.034549406141103065,
"lower": -0.06078258675544725,
"upper": -0.008577861012001597
},
"group_1": "69 of 944",
"group_2": "100 of 929",
"difference": "-3.5 points",
"interval": "-6.1 to -0.9",
"trial_title": "An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart)(MK-0653A-043 AM4)(COMPLETED)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=189",
"request_id": "o42TFfHE8hzF83NA"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant